April is National Esophageal Cancer awareness month, and CPSI shares in the fight to develop new therapies for esophageal cancer.

Owego, NY – In conjunction with National Esophageal Cancer awareness month, CPSI has announced the development of a next generation medical device designed to freeze cancer in situ (in place within the body), thereby destroying the tumor.  CPSI’s SCN Platform has the potential to revolutionize the treatment of diseases ranging from pancreatic cancer, Barrett’s esophagus and esophageal cancer to cardiac arrhythmias, potentially impacting millions of patients annually worldwide.  The SCN device converts liquid nitrogen (LN2) to Supercritical Nitrogen (SCN) then, using a minimally invasive approach, delivers the cryogen via specialized cryoprobes to freeze a targeted tissue.  CPSI, in conjunction with collaborators at Johns Hopkins Medical, have conducted a series of preliminary studies demonstrating the successful delivery of an ultra-cold (<-170°C), highly effective lethal insult (ablative dose) within a matter of minutes.  Continued research and development efforts in esophageal cancer are also supported by a grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program. With these results, the team is now focused on development of the SCN Platform for the treatment of several gastroenterological diseases, including esophageal and pancreatic cancer.

Click here to read the full press release: CPSI’s SCN cryoablation technology platform will provide an advanced, cost effective, minimally invasive treatment strategy for pancreatic, esophageal and other gastroenterological cancers.

View other CPSI Biotech news and recent patent announcements